Summary
The provided AI statements focus on appetite/weight mechanisms and study outcomes, but the supplied label excerpts (Sections 5.1 and 17) address only suicidal thoughts/behaviors in adolescents/young adults. Therefore, none of the appetite/weight-related claims are supported or verifiable against the provided FDA-approved prescribing information.
Category Scores
Accurate Statements
The label states that suicidal thoughts and behaviors are increased with antidepressants/SSRIs (including escitalopram) in patients age 24 years and younger, and that monitoring is recommended especially during the initial few months and at times of dosage changes.
Supported by provided FDA label excerpt Sections 5.1 and 17 (pooled analyses; monitor closely during initial months and dose changes; counsel patients/families/caregivers to report emergence).
Unsupported Statements
Escitalopram is an SSRI medication.
Not supported or addressed in the provided label excerpts (only suicidal thoughts/behaviors sections were supplied).
Escitalopram is commonly used to treat depression.
Not addressed in the provided label excerpts.
Escitalopram is commonly used to treat anxiety disorders.
Not addressed in the provided label excerpts.
Escitalopram has been associated with changes in appetite in some individuals.
Not addressed in the provided label excerpts.
Escitalopram can affect appetite and weight.
Not addressed in the provided label excerpts.
Escitalopram has been shown to cause weight gain in approximately 10% of patients.
Not addressed in the provided label excerpts; specific numeric incidence not verifiable.
Some individuals may experience appetite suppression instead of weight gain with escitalopram.
Not addressed in the provided label excerpts.
In a study, patients taking escitalopram for depression reported decreased appetite compared to those taking placebo.
Not addressed in the provided label excerpts; study-specific comparative claim not verifiable.
In a study, patients taking escitalopram for depression had weight loss compared to those taking placebo.
Not addressed in the provided label excerpts; study-specific comparative claim not verifiable.
In a study, escitalopram was associated with significant weight gain in patients with anxiety disorders.
Not addressed in the provided label excerpts; study-specific comparative claim not verifiable.
In a study, escitalopram was associated with increased appetite in patients with anxiety disorders.
Not addressed in the provided label excerpts; study-specific comparative claim not verifiable.
The mechanisms underlying the effect of escitalopram on appetite are not fully understood.
Not addressed in the provided label excerpts.
Escitalopram may influence serotonin levels in the brain.
Not addressed in the provided label excerpts.
Serotonin levels in the brain can affect hunger and satiety signals.
Not addressed in the provided label excerpts.
Individual responses to escitalopram can vary significantly.
Not addressed in the provided label excerpts.
Appetite changes may be influenced by dosage.
Not addressed in the provided label excerpts.
Appetite changes may be influenced by duration of treatment.
Not addressed in the provided label excerpts.
Appetite changes may be influenced by individual metabolism.
Not addressed in the provided label excerpts.
Contradictions
Important Omissions
Any label-supported description of appetite/weight changes, including whether they are adverse reactions and any rates/percentages, monitoring, or clinical guidance, would be material to evaluating the appetite/weight claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Because the only provided label excerpts relate to suicidal thoughts/behaviors and do not discuss appetite/weight, the appetite/weight claims cannot be verified against the provided prescribing information; this limits label alignment rather than directly demonstrating a label-based safety conflict.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements (appetite/weight/mechanism and study-based claims) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to label content available in the supplied excerpts (Sections 5.1 and 17). If appetite/weight information is needed, provide the corresponding FDA label sections (e.g., Adverse Reactions or Clinical Studies) to support specific rates and comparative outcomes.